Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01UFN
|
|||
| Former ID |
DNAP001360
|
|||
| Drug Name |
Falecalcitrol
|
|||
| Synonyms |
Falecalcitriol; falecalcitriol; Flocalcitriol; 83805-11-2; calcitriol hexafluoride; Hornel, Fulstan; Falecalcitriol [INN]; ST-630; ST 630; Fulstan; Ro 23-4194; UNII-G70A8514T8; C27H38F6O3; Hornel; 26,26,26,27,27,27-Hexafluoro-1,25-dihydroxyvitamin D3; G70A8514T8; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; Hexafluorocalcitriol; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol,; Fulstan (TN); Horner (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyperparathyroidism [ICD-11: 5A51; ICD-9: 252.02, 588.81] | Approved | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H38F6O3
|
|||
| Canonical SMILES |
CC(CCCC(C(F)(F)F)(C(F)(F)F)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C
|
|||
| InChI |
1S/C27H38F6O3/c1-16(6-4-13-25(36,26(28,29)30)27(31,32)33)21-10-11-22-18(7-5-12-24(21,22)3)8-9-19-14-20(34)15-23(35)17(19)2/h8-9,16,20-23,34-36H,2,4-7,10-15H2,1,3H3/b18-8+,19-9-/t16-,20-,21-,22+,23+,24-/m1/s1
|
|||
| InChIKey |
XPYGGHVSFMUHLH-UUSULHAXSA-N
|
|||
| CAS Number |
CAS 83805-11-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7848725, 8616931, 12014211, 14715097, 14762971, 14885230, 39315677, 50045654, 50737920, 53788433, 57358562, 113856645, 126665072, 135027175, 135650250, 137116359, 139732774, 152258775, 160647626, 160682006, 162262992, 184812081, 198979409, 223682754, 223860399, 226395869, 240218173, 251916470, 251917818, 252225012, 252478834
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vitamin D3 receptor (VDR) | Target Info | Agonist | [2] |
| KEGG Pathway | Endocrine and other factor-regulated calcium reabsorption | |||
| Mineral absorption | ||||
| Tuberculosis | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Panther Pathway | Vitamin D metabolism and pathway | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | |||
| Direct p53 effectors | ||||
| RXR and RAR heterodimerization with other nuclear receptor | ||||
| Retinoic acid receptors-mediated signaling | ||||
| Validated transcriptional targets of deltaNp63 isoforms | ||||
| Validated transcriptional targets of TAp63 isoforms | ||||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | Ovarian Infertility Genes | |||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Vitamin D Receptor Pathway | ||||
| Drug Induction of Bile Acid Pathway | ||||
| Nuclear Receptors | ||||
| Vitamin D Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Bioorg Med Chem. 2000 Aug;8(8):2157-66. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.